Obagi Medical Shares New Data on Recent Innovations at Music City Symposium for Cosmetic Advances & Laser Education (SCALE) Meeting
Rhea-AI Summary
Obagi Medical (NASDAQ: WALD), part of Waldencast, shared new clinical and real-world data at the Music City SCALE meeting. Highlights include interim results from the ALOHA real-world evaluation of Obagi Saypha MagIQ filler and first data from the NU-GEN Cellular Renewal Serum clinical program.
The ALOHA interim data show 94% of injectors believe MagIQ complements existing fillers, with 43% of patients also evaluating Obagi skincare. NU-GEN is clinically proven to visibly rewind skin’s age by up to six years while addressing nine signs of aging.
Positive
- None.
Negative
- None.
News Market Reaction – WALD
In the May 15 session, WALD declined 9.82%, reflecting a notable negative market reaction. Argus tracked a trough of -5.2% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 30 | Product launch | Positive | +16.6% | Launch of new Sun Shield Mineral UV Barrier Protect SPF 40 sunscreen. |
| Apr 28 | Regulatory update | Positive | -2.1% | SEC concluded investigation without intent to recommend enforcement action. |
| Mar 24 | Product launch | Positive | -7.4% | Launch of NU-GEN Cellular Renewal Serum with favorable clinical metrics. |
| Mar 19 | Collaboration | Positive | -8.3% | Collaboration with ProMD in ALOHA Program for saypha MagIQ real-world data. |
| Mar 13 | Earnings results | Positive | +8.2% | Q4/FY2025 results with $272.1M revenue, positive adjusted EBITDA, lower net debt. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows mixed reactions, with several positive product or program updates followed by negative price moves, but product launches and earnings occasionally aligning with gains.
Over the past six months, WALD has reported Obagi product launches, real-world evidence programs, and Q4/FY2025 results. Notably, a sunscreen launch on Apr 30 saw a 16.64% gain, while NU-GEN™ and ALOHA announcements in March coincided with declines of 7.38% and 8.28%. Earnings on Mar 13 with $272.1M FY revenue and $16.1M adjusted EBITDA aligned with an 8.22% rise. Today’s clinical and real-world data update extends this stream of Obagi-focused innovation news.
Key Terms
hyaluronic acid dermal filler medical
fda regulatory
nad+ medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Data from the ALOHA Program and NU-GEN™ Cellular Renewal Serum Showcase Results to Help Drive Practice Success
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD), today announced new data shared at the Music City SCALE meeting taking place May 13-17 in Nashville, TN.
- Results from a 12-Week Open-Label Study Evaluating the Efficacy and Tolerability of Obagi NU-GEN Cellular Renewal Serum on Wrinkles, Hyperpigmentation, Radiance, Texture, Firmness, Plumpness, and Perceived Skin Age: ePoster Dr. Todd Schlessinger, MD
- Interim Results from a large scale Multiple Practitioner Real-World Evaluation of a Novel Hyaluronic Acid Dermal Filler in Conjunction with Medical Grade Skin Care: ePoster Dr. Carolyn Jacob, MD
“As one of the pivotal clinical sites for the FDA registration programs for the Obagi fillers, I was intrigued to do a real-world evaluation of Obagi Saypha® MagIQ™,” said Dr. Carolyn Jacob, MD. “Reviewing the results from over 300 participating sites validated the core clinical results and makes it clear that there is a place for MagIQ in most practices.”
The real-world data evaluated an interim review of the ALOHA (Aesthetic Leadership with Obagi Hyaluronic Acid) Program, a structured clinical collaboration program designed to accelerate aesthetic innovation through practice-led insight. Obagi anticipates that the ALOHA program will become the largest real-world evaluation program for a new injectable filler. The interim data highlights that
“These data points represent clinical and real-world results from our newest Obagi innovations,” stated Drew Fine, U.S. General Manager, Professional Channel. “Obagi Saypha® MagIQ™ and NU-GEN™ Cellular Renewal Serum represent meaningful advances that support practice success and highlight the benefits of looking at Obagi injectable and skincare solutions.”
The ePoster represents the first data sharing from the NU-GEN clinical program. The formula is clinically proven to visibly rewind skin’s age by up to six years1 by helping replenish skin cells with NAD+ and addressing nine signs of skin aging simultaneously.
About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024, Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand's website, https://www.obagi.com.
About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the Business Combination. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: https://ir.waldencast.com.
Media Contact:
obagi@behrmancesa.com
1 Results based on a 2025 12-week aging clinical test. Individual results may vary. Data on file at Obagi Cosmeceuticals LLC.
